88 Results for "

DM-1

" in MedChemExpress (MCE) Product Catalog:
Products (88)

88 Results for "DM-1" in MCE Product Catalog:

28
28 Publications Verification
Cat. No.: HY-19792
CAS No.: 139504-50-0
Synonyms: DM1; Maytansinoid DM1
Research Areas:  

Cancer

Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) [1] .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-101070
CAS No.: 1228105-51-8
Purity:  99.23%
Synonyms: DM1-SMCC
Research Areas:  

Cancer

SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) [1].
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9921
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine; PRO132365; T-DM 1
Research Areas:  

Cancer

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer [1] .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9921A
CAS No.: 1018448-65-1
Synonyms: Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer [1] .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12066
CAS No.: 1032823-75-8
Purity:  99.21%
Target:  

GPR119

GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-126682
CAS No.: 1464051-44-2
Purity:  99.41%
Research Areas:  

Cancer

Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB [1].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101982
CAS No.: 1281816-04-3
Purity:  99.61%
Synonyms: Lys-Nε-MCC-DM1
Research Areas:  

Cancer

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19947
CAS No.: 1393124-08-7
Synonyms: Glucagon receptor antagonists-4
Target:  

GCGR

Research Areas:  

Metabolic Disease

PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15408
CAS No.: 865759-25-7
Purity:  99.54%
Synonyms: SYR-472
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15408A
CAS No.: 1029877-94-8
Purity:  99.96%
Synonyms: SYR-472 succinate
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-19835
CAS No.: 1423018-12-5
Research Areas:  

Metabolic Disease

LY2922470 is a selective and orally active agonist for the G protein-coupled receptor 40 (GPR40). LY2922470 activates GPR40-mediated β-arrestin recruitment with EC50s of 7 nM (human GPR40), 1 nM (mouse GPR40) and 3 nM (rat GPR40). LY2922470 can be used for research of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990001
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10449A
CAS No.: 1152425-66-5
Purity:  99.20%
Synonyms: TS 071 hydrate
Target:  

SGLT

Research Areas:  

Metabolic Disease

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .
loading...
    loading...
Cat. No.: HY-126491
CAS No.: 452072-20-7
Purity:  ≥95.0%
Research Areas:  

Cancer

SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP [1].
loading...
    loading...
Cat. No.: HY-153865
CAS No.: 2401892-75-7
Purity:  99.68%
Synonyms: PF-07081532
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .
loading...
    loading...
Cat. No.: HY-136286
CAS No.: 1375089-56-7
Purity:  99.50%
Research Areas:  

Cancer

MC-DM1 is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody agent conjugate (ADC) [1].
loading...
    loading...
Cat. No.: HY-P991501
Synonyms: HcHAb18
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a Kd of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer [1] .
loading...
    loading...
Cat. No.: HY-132250
CAS No.: 1100692-14-5
Purity:  99.52%
Research Areas:  

Cancer

MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues [1] .
loading...
    loading...
Cat. No.: HY-147257
CAS No.: 1844874-26-5
Purity:  99.07%
Synonyms: HSK7653
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
loading...
    loading...
Cat. No.: HY-136717
CAS No.: 883973-99-7
Purity:  99.10%
Target:  

FBPase

Research Areas:  

Metabolic Disease

FBPase-1 inhibitor-1 (Compound 1) is an allosteric FBPase-1 inhibitor with an IC50 of 3.3 μM or 3.9 μM. FBPase-1 inhibitor-1 blocks gluconeogenesis by inhibiting FBPase-1. FBPase-1 inhibitor-1 can be used for the research of type 2 diabetes (t2dm) .
loading...
    loading...